Paper lanterns add a touch of whimsy to whatever space they're in. Here's how to easily make your own with tissue paper and ...

How to wrap a stuffy christmas holiday gift wrapping tutorial bear paper ...

Pfizer (PFE) is preparing to shut a research site and an office location in South San Francisco at the end of April, signaling a notable pullback from the Bay Area’s flagship biotech space, the San ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An illustration photo shows a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine from Skippack ...

Pfizer (PFE) and BioNTech (BNTX) have halted recruitment for a large U.S.-based clinical trial designed to test their updated COVID-19 vaccine in healthy adults aged 50-64 years, citing challenges in ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to ...

Pfizer plans to shutter its South San Francisco research offices on April 30, ending its short tenure in the city. Pfizer planted its flag in South San Francisco in 2022 when it acquired Global Blood ...

Belgian court orders Poland, Romania to honour Pfizer contracts Poland, Romania argued pandemic changes justified refusal Court dismissed these claims Pfizer expects payment, Poland considers legal ...

Beginning in 2023, Novavax embarked on an identity shift, moving away from the fully integrated business ambitions once fueled by a pandemic-era gold rush in vaccines toward a leaner structure built ...

Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while outlining a claimed edge over Pfizer’s rival candidate. But investors sent ...

Pfizer has emerged victorious in a legal brawl with Poland and Romania over contested COVID vaccine orders, with a Belgian court ordering the two countries to pay €1.9 billion ($2.2 billion). The ...

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug program. But for Valneva CEO Thomas Lingelbach, the regulatory future of the ...